Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2027

Conditions
Radiation DiseaseCognitive ImpairmentDrug Effect
Interventions
DRUG

Memantine Oral Tablet

"Oral administration of Memantine Tablets (10mg/tablet):~Week 1: 5mg in the morning. Week 2: 5mg twice daily. Week 3: 10mg in the morning, 5mg in the evening. Weeks 4-24: 10mg twice daily."

DRUG

Pioglitazone 15mg

"Simultaneous oral administration of Pioglitazone Tablets (15mg/tablet):~Weeks 1-24: 30mg once daily."

RADIATION

Hippocampal avoidance whole-brain radiotherapy (HA-WBRT)

Based on the RTOG 0933 protocol, hippocampal and perihippocampal regions are delineated, and hippocampal dose constraints are applied. The radiation dose to the perihippocampal region is determined based on the size, number, and volume of brain metastases (whole-brain radiation therapy: DT 30Gy/10F, weeks 1-2; with a simultaneous boost to the pathological local area if necessary, 10-20Gy).

All Listed Sponsors
collaborator

Guangdong Provincial People's Hospital

OTHER

collaborator

Fujian Medical University Union Hospital

OTHER

collaborator

Southern Medical University, China

OTHER

collaborator

The Affiliated Panyu Center Hospital of Guangzhou Medical University

UNKNOWN

collaborator

The Central Hospital of Shaoyang City

UNKNOWN

lead

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

OTHER

NCT06594172 - Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy | Biotech Hunter | Biotech Hunter